4D Molecular Therapeutics (FDMT) Other Non Operating Income (2020 - 2026)
4D Molecular Therapeutics' (FDMT) quarterly Other Non Operating Income came in at -$4000.0 in Q1 2026, down 105.97% year-on-year from $67000.0 in Q1 2025, and up 81.82% on a QoQ basis from -$22000.0 in Q4 2025.
4D Molecular Therapeutics (FDMT) Other Non Operating Income (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has 7 years of Other Non Operating Income data on file, last reported at -$4000.0 in Q1 2026.
- On a quarterly basis, Other Non Operating Income fell 105.97% year-over-year to -$4000.0 in Q1 2026; TTM through Mar 2026 was -$108000.0, a N/A change from a year earlier, with the FY2025 full-year figure at -$37000.0, up 51.95% from the prior year.
- Other Non Operating Income for Q1 2026 stood at -$4000.0, up from -$22000.0 in the prior quarter.
- Over the last five years, Other Non Operating Income for FDMT reached as high as $67000.0 in Q1 2025 and fell as low as -$158000.0 in Q3 2023.
- Historically, Other Non Operating Income has averaged -$20750.0 across 5 years, with a median of -$15000.0 in 2023.
- On a YoY basis, Other Non Operating Income climbed as much as 770.0% in 2025 and fell as far as 2000.0% in 2025.
- Year by year, Other Non Operating Income stood at $3000.0 in 2022, then plunged by 466.67% to -$11000.0 in 2023, then sank by 90.91% to -$21000.0 in 2024, then declined by 4.76% to -$22000.0 in 2025, then soared by 81.82% to -$4000.0 in 2026.
- Per Business Quant data, the three most recent Other Non Operating Income figures were -$4000.0 in Q1 2026, -$22000.0 in Q4 2025, and -$21000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | 4D Molecular Therapeutics | 691.54 Mn | 300.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4,000.00 |
| Dec 31, 2025 | -22,000.00 |
| Sep 30, 2025 | -21,000.00 |
| Jun 30, 2025 | -61,000.00 |
| Mar 31, 2025 | 67,000.00 |
| Dec 31, 2024 | -21,000.00 |
| Sep 30, 2024 | -1,000.00 |
| Jun 30, 2024 | -45,000.00 |
| Mar 31, 2024 | -10,000.00 |
| Dec 31, 2023 | -11,000.00 |
| Sep 30, 2023 | -158,000.00 |
| Jun 30, 2023 | 8,000.00 |
| Mar 31, 2023 | -19,000.00 |
| Dec 31, 2022 | 3,000.00 |
| Sep 30, 2022 | 9,000.00 |
| Mar 31, 2022 | -46,000.00 |
| Dec 31, 2021 | -7,000.00 |
| Sep 30, 2021 | -13,000.00 |
| Mar 31, 2021 | -101,000.00 |
| Dec 31, 2020 | -129,000.00 |